Facts and Hopes for Gut Microbiota Interventions in Cancer Immunotherapy.
Facts and Hopes for Gut Microbiota Interventions in Cancer Immunotherapy.
复制标题
癌症免疫疗法中肠道菌群干预措施的事实和希望。
DOI：
10.1158/1078-0432.ccr-21-1129
复制
发表时间：
2022-10-14
期刊：
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
靶向细胞毒性T淋巴细胞相关抗原4（CTLA-4）和程序性死亡1（PD-1）蛋白的免疫检查点抑制剂（ICI）改变了晚期癌症的管理。许多肿瘤内在因素调节对此类疗法的免疫学和临床反应，但大量证据也表明肠道微生物组参与了反应。肠道微生物组，包括生活在人类消化道中的细菌，古细菌，真菌和病毒，是宿主免疫的既定决定因素，但其对小鼠和人类癌症患者ICI治疗反应的影响最近才被认识到。优化微生物群组成以改善免疫治疗结果的治疗干预在患有癌症的小鼠和人类中显示出希望。在这篇综述中，我们讨论了基于肠道微生物组的癌症治疗的基本原理，早期临床试验的结果以及未来可能的发展。
Immune checkpoint inhibitors (ICI) targeting cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) and programmed death 1 (PD-1) proteins transformed the management of advanced cancers. Many tumor-intrinsic factors modulate immunological and clinical responses to such therapies, but ample evidence also implicates the gut microbiome in responses. The gut microbiome, comprising the bacteria, archaea, fungi, and viruses that live in the human digestive tract, is an established determinant of host immunity, but its impact on response to ICI therapy in mice and humans with cancer has only recently been appreciated. Therapeutic interventions to optimize microbiota composition to improve immunotherapy outcomes show promise in mice and humans with cancer. In this review, we discuss the rationale for gut microbiome–based cancer therapies, the results from early-phase clinical trials, and possible future developments.